Logo Logo
Exportieren als [RSS feed] RSS 1.0 [RSS2 feed] RSS 2.0
Gruppiert nach: Dokumententyp | Veröffentlichungsdatum
Anzahl der Publikationen: 10

Zeitschriftenartikel

Sessa, C.; Balmana, J.; Bober, S. L.; Cardoso, M. J.; Colombo, N.; Curigliano, G.; Domchek, S. M.; Evans, D. G.; Fischerova, D.; Harbeck, N.; Kuhl, C.; Lemley, B.; Levy-Lahad, E.; Lambertini, M.; Ledermann, J. A.; Loibl, S.; Phillips, K. -A. und Paluch-Shimon, S. (2022): Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline. In: Annals of Oncology, Bd. 34, Nr. 1: S. 33-47

Schrodi, S.; Braun, M.; Andrulat, A.; Harbeck, N.; Mahner, S.; Kiechle, M.; Klein, E.; Schnelzer, A.; Schindlbeck, C.; Bauerfeind, I.; Schubert-Fritschle, Gabriele; Nekljudova, V.; Mayr, D.; Weichert, W.; Denkert, C.; Loibl, S. und Engel, J. (2021): Outcome of breast cancer patients with low hormone receptor positivity. Analysis of a 15-year population-based cohort. In: Annals of Oncology, Bd. 32, Nr. 11: S. 1410-1424 [PDF, 1MB]

Gennari, A.; Andre, F.; Barrios, C. H.; Cortes, J.; de Azambuja, E.; DeMichele, A.; Dent, R.; Fenlon, D.; Gligorov, J.; Hurvitz, S. A.; Im, S. -a.; Krug, D.; Kunz, W. G.; Loi, S.; Penault-Llorca, F.; Ricke, J.; Robson, M.; Rugo, H. S.; Saura, C.; Schmid, P.; Singer, C. F.; Spanic, T.; Tolaney, S. M.; Turner, N. C.; Curigliano, G.; Loibl, S.; Paluch-Shimon, S. und Harbeck, N. (2021): ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. In: Annals of Oncology, Bd. 32, Nr. 12: S. 1475-1495

Turner, N. C.; Slamon, D. J.; Ro, J.; Bondarenko, I; Im, S-A; Masuda, N.; Colleoni, M.; DeMichele, A.; Loi, S.; Verma, S.; Iwata, H.; Harbeck, N.; Loibl, S.; Andre, F.; Puyana Theall, K.; Huang, X.; Giorgetti, C.; Huang Bartlett, C. und Cristofanilli, M. (2018): Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. In: New England Journal of Medicine, Bd. 379, Nr. 20: S. 1926-1936

Witzel, I.; Laakmann, E.; Weide, R.; Neunhoeffer, T.; Park-Simon, T. -J.; Schmidt, M.; Fasching, P. A.; Hesse, T.; Polasik, A.; Mohrmann, S.; Wuerschmidt, F.; Schem, C.; Bechtner, C.; Würstlein, R.; Fehm, T.; Moebus, V.; Burchardi, N.; Loibl, S. und Müller, V. (2018): Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry. In: European Journal of Cancer, Bd. 102: S. 1-9

Mackelenberg, M. van; Denkert, C.; Nekljudova, V.; Karn, T.; Schem, C.; Marme, F.; Stickeler, E.; Jackisch, C.; Hanusch, C.; Huober, J.; Fasching, P.; Blohmer, J.-U.; Kummel, S.; Müller, V.; Schneeweiss, A.; Untch, M.; Minckwitz, G. von; Weber, K. und Loibl, S. (2017): Outcome after neoadjuvant chemotherapy in progesterone receptor negative breast cancer patients - A pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials. In: Cancer Research, Bd. 77

Fasching, P. A.; Loibl, S.; Eidtmann, H.; Tesch, H.; Untch, M.; Hilfrich, J.; Schem, C.; Rezai, M.; Gerber, B.; Costa, S. D.; Blohmer, J. U.; Fehm, T. N.; Huober, J.; Liedtke, C.; Müller, V.; Nekljudova, V.; Weber, K.; Rack, B.; Rübner, M.; Wang, L.; Ingle, J. N.; Weinshilboum, R. M.; Minckwitz, G. von und Couch, F. (2016): BRCA mutations, therapy response and prognosis in the neoadjuvant GeparQuinto study. In: Cancer Research, Bd. 76

Harbeck, N.; Iyer, S.; Turner, N.; Cristofanilli, M.; Ro, J.; André, F.; Loi, S.; Verma, S.; Iwata, H.; Bhattacharyya, H.; Theall, K. Puyana; Bartlett, C. H. und Loibl, S. (2016): Quality of life with palbociclib plus fulvestrant in previously treated hormone receptor-positive, HER2-negative metastatic breast cancer: patient-reported outcomes from the PALOMA-3 trial. In: Annals of Oncology, Bd. 27, Nr. 6: S. 1047-1054

Loibl, S.; Demichele, A.; Turner, N. M.; Cristofanilli, M.; Loi, S.; Verma, S.; Bhattacharyya, H.; Ke, Z.; Giorgetti, C.; Bartlett, C. H.; Iyer, S.; Colleoni, M.; Masuda, N.; Im, S.-A. und Harbeck, N. (2016): Impact of palbociclib plus fulvestrant on patient reported general health status compared with fulvestrant alone in HR +, HER2-metastatic breast cancer. In: Annals of Oncology, Bd. 27

Janning, M.; Müller, V; Vettorazzi, E.; Cubas-Cordova, M.; Gensch, V; Ben Batalla, I; Eulenburg, C. zu; Schem, C.; Fasching, P. A.; Schnappauf, B.; Karn, T.; Fehm, T.; Just, M.; Kühn, T.; Holms, F.; Overkamp, F.; Krabisch, P.; Rack, B.; Denkert, C.; Untch, M.; Tesch, H.; Rezai, M.; Kittel, K.; Pantel, K.; Bokemeyer, C.; Loibl, S.; Minckwitz, G. von und Loges, S. (2016): Serum carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial. In: Oncology Research and Treatment, Bd. 39: S. 185

Diese Liste wurde am Sat Dec 21 23:36:02 2024 CET erstellt.